company background image
NGM logo

NGM Biopharmaceuticals Informe acción NasdaqGS:NGM

Último precio

US$1.54

Capitalización de mercado

US$128.5m

7D

-3.1%

1Y

-59.8%

Actualizada

05 Apr, 2024

Datos

Finanzas de la empresa +

NGM Biopharmaceuticals, Inc.

Informe acción NasdaqGS:NGM

Capitalización de mercado: US$128.5m

Resumen de acción NGM

NGM Biopharmaceuticals, Inc. es una empresa biofarmacéutica dedicada al descubrimiento y desarrollo de nuevas terapias para el tratamiento de enfermedades hepáticas y metabólicas, retinianas y cáncer.

Análisis fundamental de NGM
Puntuación del snowflake
Valoración0/6
Crecimiento futuro2/6
Rendimiento pasado0/6
Salud financiera6/6
Dividendos0/6

Competidores de NGM Biopharmaceuticals, Inc.

Historial de precios y rendimiento

Resumen de todos los máximos históricos, cambios y caídas de precios de NGM Biopharmaceuticals
Precios históricos de las acciones
Precio actual de la acciónUS$1.54
Máximo en las últimas 52 semanasUS$4.69
Mínimo de 52 semanasUS$0.60
Beta1.27
1Cambio en 1 mes1.32%
Variación en 3 meses14.93%
Cambio de 1 año-59.79%
3Variación en 3 años-93.94%
Variación en 5 años-90.41%
Variación desde la OPV-89.52%

Noticias y actualizaciones recientes

Recent updates

What NGM Biopharmaceuticals, Inc.'s (NASDAQ:NGM) 32% Share Price Gain Is Not Telling You

Dec 19
What NGM Biopharmaceuticals, Inc.'s (NASDAQ:NGM) 32% Share Price Gain Is Not Telling You

We're A Little Worried About NGM Biopharmaceuticals' (NASDAQ:NGM) Cash Burn Rate

Oct 05
We're A Little Worried About NGM Biopharmaceuticals' (NASDAQ:NGM) Cash Burn Rate

Some Analysts Just Cut Their NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Estimates

Aug 09
Some Analysts Just Cut Their NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Estimates

Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Could Be Quite Risky

Jun 27
Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Could Be Quite Risky

NGM Biopharmaceuticals, Inc.'s (NASDAQ:NGM) Business Is Trailing The Industry But Its Shares Aren't

Apr 17
NGM Biopharmaceuticals, Inc.'s (NASDAQ:NGM) Business Is Trailing The Industry But Its Shares Aren't

We Think NGM Biopharmaceuticals (NASDAQ:NGM) Needs To Drive Business Growth Carefully

Dec 20
We Think NGM Biopharmaceuticals (NASDAQ:NGM) Needs To Drive Business Growth Carefully

NGM Biopharma sinks ~72% after phase 2 trial of its eye degeneration treatment fails

Oct 17

NGM Biopharmaceuticals appoints CFO Siobhan Nolan Mangini to the additional role of President

Jun 30

NGM Biopharmaceuticals: Eye Disorder Data Due Second Half Of 2022

Jun 21

Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth

Jun 15
Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth

Analysts Are Betting On NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) With A Big Upgrade This Week

May 09
Analysts Are Betting On NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) With A Big Upgrade This Week

NGM Biopharmaceuticals: How They Changed A Dead End To A Crossroad

Apr 26

Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth

Feb 21
Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth

We're Hopeful That NGM Biopharmaceuticals (NASDAQ:NGM) Will Use Its Cash Wisely

Nov 08
We're Hopeful That NGM Biopharmaceuticals (NASDAQ:NGM) Will Use Its Cash Wisely

Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth

Jul 09
Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth

NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Annual Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Mar 06
NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Annual Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Rentabilidad de los accionistas

NGMUS PharmaceuticalsMercado US
7D-3.1%-3.7%-1.6%
1Y-59.8%17.2%30.8%

Rentabilidad vs. Industria: NGM underperformed the US Pharmaceuticals industry which returned 15.5% over the past year.

Rentabilidad vs. Mercado: NGM underperformed the US Market which returned 24.7% over the past year.

Volatilidad de los precios

Is NGM's price volatile compared to industry and market?
NGM volatility
NGM Average Weekly Movement10.3%
Pharmaceuticals Industry Average Movement9.3%
Market Average Movement6.0%
10% most volatile stocks in US Market14.9%
10% least volatile stocks in US Market2.9%

Precio estable de las acciones: NGM's share price has been volatile over the past 3 months.

Volatilidad a lo largo del tiempo: NGM's weekly volatility (10%) has been stable over the past year.

Acerca de la empresa

FundadaEmpleadosCEOPágina web
2007138David Woodhousewww.ngmbio.com

NGM Biopharmaceuticals, Inc. es una empresa biofarmacéutica dedicada al descubrimiento y desarrollo de nuevas terapias para tratar enfermedades hepáticas y metabólicas, enfermedades de la retina y cáncer. La empresa desarrolla el NGM707, un anticuerpo monoclonal antagonista dual del transcrito 2 similar a la inmunoglobulina/transcrito 4 similar a la inmunoglobulina que se encuentra en ensayos clínicos de fase I/II para el tratamiento de pacientes con tumores sólidos metastásicos avanzados; y Aldafermin, un análogo de ingeniería del factor 19 de crecimiento de fibroblastos de la hormona humana, que se encuentra en ensayos clínicos de fase IIb para el tratamiento de la colangitis esclerosante primaria y la esteatohepatitis no alcohólica. También desarrolla el NGM120, un anticuerpo antagonista del GFRAL, que está en ensayos clínicos de fase II para tratar la hiperémesis gravídica; el NGM831 y el NGM438, que están en ensayos clínicos de fase I/II para el tratamiento de tumores sólidos avanzados; y el NGM621, un anticuerpo monoclonal en ensayos clínicos de fase II para el tratamiento de la atrofia geográfica.

Resumen de fundamentos de NGM Biopharmaceuticals, Inc.

¿Cómo se comparan los beneficios e ingresos de NGM Biopharmaceuticals con su capitalización de mercado?
Estadísticas fundamentales de NGM
Capitalización bursátilUS$128.53m
Beneficios(TTM)-US$142.37m
Ingresos (TTM)US$4.42m

29.1x

Ratio precio-ventas (PS)

-0.9x

Ratio precio-beneficio (PE)

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de NGM
IngresosUS$4.42m
Coste de los ingresosUS$114.23m
Beneficio bruto-US$109.81m
Otros gastosUS$32.56m
Beneficios-US$142.37m

Últimos beneficios comunicados

Dec 31, 2023

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)-1.71
Margen bruto-2,486.12%
Margen de beneficio neto-3,223.34%
Ratio deuda/patrimonio0%

¿Cómo se ha desempeñado NGM a largo plazo?

Ver rendimiento histórico y comparativa